Pirprofen (Rengasil) in the treatment of juvenile rheumatoid arthritis. A segment I study
Bass, J.C.; Giannini, E.H.; Brewer, E.J.; Athreya, B.H.; Brandstrup, N.E.; Goldsmith, D.P.; Miller, J.J.; Pachman, L.M.
Journal of Rheumatology 9(1): 140-143
1982
ISSN/ISBN: 0315-162X PMID: 7086772 Document Number: 193440
Patients (32) with JRA were enrolled in a 4-wk, open-labeled, noncontrolled multicenter trial of pirprofen. An initial dose of .apprx. 300 mg/m2 per day (range 250-330) was gradually increased to a maximum of 600 mg/m2 per day (range 413-761). The medication was provided as an aqueous suspension (10 mg/ml) and was given 4 times/day. Efficacy analysis showed significant decreases occurred in the duration of morning stiffness, travel time, grip strength and the severity of swelling score (in all cases P < 0.05 based on the paired Student t test, 2-tailed). Nineteen patients reported a total of 27 adverse experiences, 6 of which were attributable to pirprofen. At the dosages used, pirprofen seems to be very similar in efficacy and safety to other nonsteroidal antiinflammatory drugs investigated in children with JRA.